The “Chronic Kidney Disease - Competitive Landscape and Clinical Trial Analysis, 2026,” report provides comprehensive insights about 90+ companies and 100+ drugs in Chronic Kidney Disease Competitive landscape. It covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
CKD often develops silently, particularly during its early stages, and may remain undiagnosed until substantial loss of kidney function has occurred. Progressive CKD is associated with several important complications, including cardiovascular disease, anemia, mineral and bone disorders, electrolyte abnormalities, and fluid overload. As kidney function declines further, patients may progress to kidney failure and require kidney replacement therapy, such as dialysis or kidney transplantation. Research has also highlighted considerable disparities in CKD burden and access to kidney care across countries and regions, emphasizing the need for improved early detection and healthcare strategies.
The management of CKD focuses on identifying the underlying cause, slowing disease progression, reducing cardiovascular risk, and managing associated complications. Evidence-based strategies include effective control of blood pressure and diabetes, reduction of albuminuria, and the use of kidney-protective pharmacological therapies where clinically appropriate. Early diagnosis is particularly important because timely intervention can delay disease progression and potentially reduce the need for dialysis or transplantation. Consequently, recent research increasingly emphasizes population-level prevention, screening of high-risk individuals, and equitable access to effective CKD care as essential components of addressing the growing global burden of the disease.
Eli Lilly and Company is a US-based global pharmaceutical company focused on the discovery, development, and commercialization of innovative medicines across diabetes, obesity, cardiovascular and renal diseases, oncology, immunology, and neuroscience. The company has a strong presence in cardiometabolic medicine and collaborates with Boehringer Ingelheim on the development and commercialization of Jardiance (empagliflozin), a major therapy within the SGLT2 inhibitor class. Through this collaboration, Eli Lilly has expanded its presence in chronic kidney disease (CKD) by supporting the development of therapies that address kidney disease progression and associated cardiovascular risks.
Further product details are provided in the report……..
This product will be delivered within 2-4 business days.
Geography Covered
- Global coverage
Chronic Kidney Disease: Understanding
Chronic Kidney Disease: Overview
Chronic Kidney Disease (CKD) is a long-term and progressive disorder characterized by persistent impairment of kidney structure or function. It is associated with a gradual reduction in the ability of the kidneys to remove metabolic waste, regulate fluid and electrolyte balance, and maintain overall physiological homeostasis. Research from the Global Burden of Disease (GBD) Study has demonstrated that CKD represents a substantial and growing global health burden, with diabetic kidney disease accounting for a major proportion of CKD-related disability. The increasing prevalence of diabetes, hypertension, obesity, and ageing populations continues to contribute significantly to the rising burden of CKD worldwide.CKD often develops silently, particularly during its early stages, and may remain undiagnosed until substantial loss of kidney function has occurred. Progressive CKD is associated with several important complications, including cardiovascular disease, anemia, mineral and bone disorders, electrolyte abnormalities, and fluid overload. As kidney function declines further, patients may progress to kidney failure and require kidney replacement therapy, such as dialysis or kidney transplantation. Research has also highlighted considerable disparities in CKD burden and access to kidney care across countries and regions, emphasizing the need for improved early detection and healthcare strategies.
The management of CKD focuses on identifying the underlying cause, slowing disease progression, reducing cardiovascular risk, and managing associated complications. Evidence-based strategies include effective control of blood pressure and diabetes, reduction of albuminuria, and the use of kidney-protective pharmacological therapies where clinically appropriate. Early diagnosis is particularly important because timely intervention can delay disease progression and potentially reduce the need for dialysis or transplantation. Consequently, recent research increasingly emphasizes population-level prevention, screening of high-risk individuals, and equitable access to effective CKD care as essential components of addressing the growing global burden of the disease.
Report Highlights
- In August 2026, Vertex Pharmaceuticals announced the completion of patient enrollment in AGLOW, a Phase 2 proof-of-concept clinical study evaluating VX-407 for Autosomal Dominant Polycystic Kidney Disease (ADPKD).
- In July 2026, Arnatar Therapeutics announced that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) cleared its clinical trial application for ART5, a first-in-class up-regulating antisense oligonucleotide (ASO) designed to restore polycystin-1 production for the treatment of autosomal dominant polycystic kidney disease (ADPKD). The Company expects to initiate a first-in-human single ascending dose study in healthy volunteers in the third quarter of 2026, followed by a Phase Ib study in patients with ADPKD in the first half of 2027.
- In June 2026, SCYNEXIS, Inc. announced the initiation of a Phase I study of SCY-770, a first-in-class, potent and direct AMP-activated protein kinase (AMPK) activator being developed for the treatment of autosomal dominant polycystic kidney disease (ADPKD). The study will evaluate the pharmacokinetics and food effect of two dosing regimens to support dose selection for a planned Phase II proof-of-concept study in patients with ADPKD.
- In June 2026, Rege Nephro Co., Ltd. announced the completion of a first-close fundraising of USD 7.6 million (JPY 1.22 billion), with the financing expected to reach USD 10.6 million following the final second close. The proceeds will support the commercialization and global licensing activities of RN-014, a small-molecule therapy for autosomal dominant polycystic kidney disease (ADPKD), which has reached the last patient last visit milestone in its Phase IIa clinical trial.
- In June 2026, Unicycive Therapeutics announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for its New Drug Application (NDA) for oxylanthanum carbonate (OLC), an investigational treatment for hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis. The FDA cited deficiencies at a third-party manufacturing facility and did not identify new concerns regarding the drug's safety or efficacy or request additional clinical data.
- In May 2026, Bayer announced that the FDA accepted its supplemental New Drug Application (sNDA) and granted Priority Review to KERENDIA® (finerenone) for the treatment of adults with type 1 diabetes and chronic kidney disease (CKD). The application was supported by the Phase III FINE-ONE study, in which finerenone demonstrated an approximately 25% reduction in urine albumin-to-creatinine ratio compared with placebo over six months.
- In March 2026, SCYNEXIS, Inc. announced the acquisition of PXL770 from Poxel SA for a total potential consideration of up to USD 196 million. Under the agreement, Poxel received an upfront payment of USD 8 million, with up to USD 8 million in near-term development milestone payments and up to USD 180 million in commercial milestone payments. SCYNEXIS is developing PXL770, subsequently designated SCY-770, as a potential treatment for autosomal dominant polycystic kidney disease.
- In March 2026, R1 Therapeutics launched with an oversubscribed USD 77.5 million Series A financing round to advance AP306, a first-in-class pan-phosphate transporter inhibitor for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis. The company secured exclusive rights outside Greater China and planned to initiate mid-stage clinical development of AP306 in 2026.
Chronic Kidney Disease: Company and Product Profiles (Marketed Therapies)
- Company Overview: AstraZeneca
Product Description: Farxiga (Dapagliflozin)
Farxiga (dapagliflozin) is an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor developed by AstraZeneca. It selectively inhibits SGLT2 in the proximal renal tubules, reducing sodium and glucose reabsorption and promoting natriuresis and glucosuria. These effects help reduce intraglomerular pressure and provide kidney-protective benefits that can slow CKD progression. Farxiga received US FDA approval for the treatment of CKD on April 30, 2021. It is indicated to reduce the risk of sustained decline in estimated glomerular filtration rate (eGFR), end-stage kidney disease (ESKD), cardiovascular death, and hospitalization for heart failure in adults with CKD at risk of disease progression.- Company Overview: Boehringer Ingelheim/ Eli Lilly and Company
Eli Lilly and Company is a US-based global pharmaceutical company focused on the discovery, development, and commercialization of innovative medicines across diabetes, obesity, cardiovascular and renal diseases, oncology, immunology, and neuroscience. The company has a strong presence in cardiometabolic medicine and collaborates with Boehringer Ingelheim on the development and commercialization of Jardiance (empagliflozin), a major therapy within the SGLT2 inhibitor class. Through this collaboration, Eli Lilly has expanded its presence in chronic kidney disease (CKD) by supporting the development of therapies that address kidney disease progression and associated cardiovascular risks.
Product Description: Jardiance (Empagliflozin)
Jardiance (empagliflozin) is an oral SGLT2 inhibitor developed by Boehringer Ingelheim and Eli Lilly. It selectively inhibits SGLT2 in the proximal renal tubules, decreasing renal reabsorption of glucose and sodium and contributing to restoration of tubuloglomerular feedback and reduction of intraglomerular pressure. These effects provide kidney-protective benefits and help slow CKD progression. Jardiance received US FDA approval for its CKD indication on September 22, 2023. It is indicated to reduce the risk of sustained decline in eGFR, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure in adults with CKD at risk of progression.- Company Overview: Bayer
Product Description: Kerendia (Finerenone)
Kerendia (finerenone) is an oral, non-steroidal mineralocorticoid receptor antagonist developed by Bayer. It selectively blocks the mineralocorticoid receptor, reducing receptor overactivation associated with inflammation and fibrosis in the kidneys and cardiovascular system, thereby helping limit progressive kidney damage and cardiorenal complications. Kerendia received US FDA approval on July 9, 2021, for CKD associated with Type 2 diabetes. It is indicated to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, nonfatal myocardial infarction, and hospitalization for heart failure in adults with CKD associated with Type 2 diabetes.Chronic Kidney Disease: Company and Product Profiles (Pipeline Therapies)
- Company Overview: Jiangsu Hengrui Pharmaceuticals
Product Description: HRS-1780
HRS-1780 is an investigational, selective non-steroidal mineralocorticoid receptor antagonist (MRA) being developed for the treatment of chronic kidney disease (CKD). By selectively blocking mineralocorticoid receptor activation, HRS-1780 is intended to reduce pathological processes associated with CKD progression, including proteinuria and progressive renal function decline. In a Phase II study, HRS-1780 demonstrated a dose-dependent reduction in albuminuria, with placebo-corrected reductions in urinary albumin-to-creatinine ratio (UACR) of 29.9% and 53.5% at Week 13 with the 10 mg and 20 mg doses, respectively. HRS-1780 is currently being evaluated in a multicenter, randomized, double-blind, placebo-controlled Phase III trial in adults with CKD, with the objective of assessing its efficacy and safety in delaying renal function decline when administered alongside standard treatment. A Phase I pharmacokinetic study in subjects with mild and moderate renal impairment also showed no significant differences in the overall pharmacokinetic and safety profiles compared with healthy subjects, supporting its further clinical development in CKD. Currently, the drug is in Phase III stage of its development for CKD.- Company Overview: Boehringer Ingelheim
Product Description: Vicadrostat
Vicadrostat (BI 690517) is an investigational, potent, and highly selective aldosterone synthase inhibitor being developed by Boehringer Ingelheim for the treatment of chronic kidney disease (CKD). The therapy is designed to inhibit the production of aldosterone, a hormone implicated in inflammation, fibrosis, and progressive cardiorenal damage. By reducing excessive aldosterone activity, vicadrostat has the potential to address pathways associated with CKD progression and reduce albuminuria. Clinical studies have demonstrated that vicadrostat, including when evaluated in combination with empagliflozin, can reduce urinary albumin-to-creatinine ratio (UACR) in patients with CKD. Vicadrostat is currently being evaluated in the Phase III EASi-KIDNEY™ clinical trial, which is assessing its efficacy and safety in combination with empagliflozin in patients with CKD at risk of disease progression, representing an advanced-stage therapeutic approach targeting residual cardiorenal risk.- Company Overview: Novo Nordisk
Product Description: NNC0519-0130
NNC0519-0130 is an investigational once-weekly subcutaneous therapy being developed by Novo Nordisk that targets the GLP-1 receptor (glucagon-like peptide-1 receptor) and the GIP receptor (glucose-dependent insulinotropic polypeptide receptor) as a dual agonist.The candidate is being evaluated in a randomized, placebo- and active-controlled, proof-of-concept and dose-finding Phase II study (NCT06717698), which is assessing its efficacy, safety, and pharmacokinetics, including its potential to reduce kidney damage and improve kidney function. The study compares different doses of NNC0519-0130 with semaglutide 1.0 mg and placebo and is expected to enroll approximately 465 participants.- Company Overview: Ingenia Therapeutics
Product Description: IGT-303
IGT-303 is an investigational, first-in-class TIE2-targeted therapy being developed by Ingenia Therapeutics for the treatment of chronic kidney disease (CKD), including diabetic kidney disease (DKD). The therapy is designed to directly activate the TIE2 signaling pathway, which plays an important role in maintaining endothelial function and vascular integrity. By activating TIE2, IGT-303 aims to address vascular dysfunction and endothelial damage, key pathological processes associated with CKD progression. IGT-303 is currently being evaluated in a Phase I/IIa clinical trial to assess its safety, tolerability, pharmacokinetics, and potential therapeutic effects in patients with CKD, representing a novel disease-modifying approach targeting the vascular component of kidney disease.- Company Overview: AstraZeneca
Product Description: AZD4248
AZD4248 is an investigational small-molecule nicotinamide N-methyltransferase (NNMT) inhibitor being developed by AstraZeneca for cardiorenal disease, including chronic kidney disease (CKD). The candidate is currently being evaluated in a Phase I, first-in-human, randomized, single-blind, placebo-controlled clinical trial (NCT07024823) involving healthy participants and patients with CKD and type 2 diabetes. The study is assessing the safety, tolerability, pharmacokinetics, and pharmacodynamics of AZD4248 following single and multiple ascending doses, including multiple-dose evaluation in participants with diabetic kidney disease.Further product details are provided in the report……..
Chronic Kidney Disease Analytical Perspective
- In-depth Commercial Assessment: Chronic Kidney Disease Collaboration Analysis by Companies
Chronic Kidney Disease Competitive Landscape
The report comprises of comparative assessment of Companies (by therapy, development stage, and technology).Chronic Kidney Disease Report Assessment
- Company Analysis
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Chronic Kidney Disease Clinical Trial Assessment
- Clinical Trial Analysis
- Clinical Trial Design Analysis
- Sponsor and Geographical Analysis
- Chronic Kidney Disease Clinical Trial Analysis
- Chronic Kidney Disease Clinical Trial Design Analysis
- Sponsor and Geographical Analysis
Key Questions
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Chronic Kidney Disease drugs?
- How many Chronic Kidney Disease drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic Kidney Disease?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Chronic Kidney Disease therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Chronic Kidney Disease and their status?
- What are the key designations that have been granted to the emerging and approved drugs?
Key Players
- Boehringer Ingelheim
- Eli Lilly and Company
- Reata Pharmaceuticals
- Novo Nordisk
- KBP Biosciences
- Prokidney
- Bayer
- Novo Nordisk
- Kibow Pharma
- XORTX Therapeutics
- AstraZeneca
- Roche
- AstraZeneca
- MC2 Therapeutics
- AstraZeneca
- Allena Pharmaceuticals
- Boehringer Ingelheim
- Boehringer Ingelheim
- SCOHIA PHARMA
- DiaMedica Therapeutics
- CinCor Pharma
- Galapagos NV
- Boehringer Ingelheim
- Bayer
- Sentien Biotechnologies, Inc.
- Regeneron Pharmaceuticals
- UnicoCell Biomed
- OccuRx
- Pharmicell
- Lisata Therapeutics
- Bayer
- Ionis Pharmaceuticals
- Merck Sharp & Dohme
- Disc Medicine
- Shandong Suncadia Medicine
Key Products
- Empagliflozin
- Dapagliflozin
- Bardoxolone methyl
- Ziltivekimab
- KBP-5074
- Renal Autologous Cell Therapy
- Finerenone
- Semaglutide
- US-APR2020
- XRx-008
- Zibotentan
- Pirfenidone
- Verinurad
- MC2-25
- AZD9977
- ALLN-346
- BI-685509
- BI 764198
- SCO-792
- DM199
- Baxdrostat
- GLPG2737
- BI 690517
- Runcaciguat
- SBI-101
- REGN5459
- ELIXCYTE
- FT011
- Cellgram-CKD
- CLBS201
- BAY3283142
- ION532
- MK-2060
This product will be delivered within 2-4 business days.
Table of Contents
IntroductionExecutive SummaryChronic Kidney Disease: Company and Product Profiles (Marketed Therapies)Chronic Kidney Disease: Company and Product Profiles (Pipeline Therapies)Clinical Trial AssessmentChronic Kidney Disease- Unmet needsChronic Kidney Disease - Market drivers and barriersAppendix
Chronic Kidney Disease: Overview
Chronic Kidney Disease -Analytical Perspective: In-depth Commercial Assessment
Competitive Landscape
Boehringer Ingelheim/ Eli Lilly and Company
Jardiance
Late Stage Products (Phase III)
Jiangsu Hengrui Pharmaceuticals
HRS-1780
Mid Stage Products (Phase II)
Novo Nordisk
NNC0519-0130
Early Stage Products (Phase I)
AstraZeneca
AZD4248
Preclinical Stage Products
Discovery Stage Products
Unknown Stage Products
Therapeutic Assessment
Clinical Trial Analysis
Clinical Trial Design Analysis
Sponsor and Geographical Analysis
Inactive Products
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Boehringer Ingelheim
- Eli Lilly and Company
- Reata Pharmaceuticals
- Novo Nordisk
- KBP Biosciences
- Prokidney
- Bayer
- Novo Nordisk
- Kibow Pharma
- XORTX Therapeutics
- AstraZeneca
- Roche
- AstraZeneca
- MC2 Therapeutics
- AstraZeneca
- Allena Pharmaceuticals
- Boehringer Ingelheim
- Boehringer Ingelheim
- SCOHIA PHARMA
- DiaMedica Therapeutics
- CinCor Pharma
- Galapagos NV
- Boehringer Ingelheim
- Bayer
- Sentien Biotechnologies, Inc.
- Regeneron Pharmaceuticals
- UnicoCell Biomed
- OccuRx
- Pharmicell
- Lisata Therapeutics
- Bayer
- Ionis Pharmaceuticals
- Merck Sharp & Dohme
- Disc Medicine
- Shandong Suncadia Medicine
